ERC Advanced Grant · 2021
Reversing T cell dysfunction in cancer by multimodal genetic screening
T cell dysfunction is a key problem in cancer, enabling not only tumorigenesis but also causing resistance to immunotherapy. Induction of immune checkpoints is a hallmark of T cell dysfunction, but clinical blockade by PD-1 and CTLA-4 antibodies solves this problem for few patients only. Dysfunction is driven also by additional mechanisms, including chronic stimulation and metabolic insufficiency. A better mechanistic understanding will be imperative for improving immunotherapy. My laboratory recently launched “ReverT”, a genome-wide CRISPR-Cas9 screening program to identify genes, ablation of which reverses dysfunction in primary T cells. To de-risk this application, we have already…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.